We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
1ADNB | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
1ADO | AdAlta Limited | 0.002 | 0.00 | 0.00% | 0.00 | 0 |
1ADOA | AdAlta Limited | 0.002 | 0.00 | 0.00% | 0.00 | 0 |
1AE | Aurora Energy Metals Ltd | 0.09 | 0.00 | 0.00% | 0.00 | 0 |
1ADNA | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
1ADN | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
14D | 1414 Degrees Limited | 0.071 | 0.00 | 0.00% | 0.00 | 0 |
14DN | 1414 Degrees Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
14DO | 1414 Degrees Limited | 0.008 | 0.00 | 0.00% | 0.00 | 0 |
1AD | AdAlta Limited | 0.028 | 0.00 | 0.00% | 0.00 | 0 |
13S | 13 Seeds Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson’s Disease (PD). The PRECEDENT Study did not meet its primary endpoint of demonstrating statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test score at Day 42. Dalzanemdor (SAGE-718) was generally well-tolerated, and there were no new safety signals observed.
Marin Software Incorporated (NASDAQ: MRIN), a leading provider of digital marketing software for performance-driven advertisers and agencies, today announced it will report financial results for the quarter ended March 31, 2024, after market close on Thursday, May 2, 2024. The company also announced it will hold a conference call on the same day at 2:00 PM Pacific Time (5:00 PM Eastern Time) to discuss its quarterly financial results. This conference call may include forward-looking statements.
Total Revenues Increased 29.8% Year-over-Year for the Fourth Quarter,55.9% Year-over-Year Growth for the Full Year 2023 149 Net New Store Openings During the Fourth Quarter,912 System-Wide Stores at Year-End 2023 18.7 Million Registered Loyalty Members at Year-End,Representing 66.3% Year-over-Year Growth SHANGHAI, China and ...
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the second fiscal quarter ended February 29, 2024.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 63,575.65 | 2,292.66 | 3.74% | 1.25T | 5,776,611,232 |
ETH | Ethereum | 3,066.67 | 81.19 | 2.72% | 368.93B | 2,614,670,234 |
USDT | Tether USD | 1.00 | 0.00005 | 0.00% | 97.84B | 438,428,571 |
BNB | Binance Coin | 549.43 | 15.26 | 2.86% | 86.83B | 452,851,219 |
SOL | Solana | 140.53 | 8.46 | 6.41% | 62.08B | 1,874,942,430 |
STETH | stETH | 3,066.16 | 89.60 | 3.01% | 29.97B | 8,355,461 |
USDC | USD Coin | 0.99998 | -0.00002 | 0.00% | 28.07B | 1,099,005,028 |
XRP | Ripple | 0.5025 | 0.0071 | 1.43% | 27.39B | 352,835,939 |
TONCOIN | Wrapped TON Coin | 6.61 | 0.512296 | 8.40% | 22.55B | 230,503,026 |
DOGE | Dogecoin | 0.15084 | 0.00308 | 2.08% | 21.62B | 668,805,651 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions